

Registered number 11326856

**Ocquila Therapeutics Limited**  
**Directors' report and financial statements**  
**for the period from incorporation (24 April 2018) to 31 December 2018**



## Ocquila Therapeutics Limited

### Company information

<b>Directors</b>	Peter Nolan Sara Hall
<b>Registered number</b>	11326856
<b>Registered office</b>	Northend Cottage, Crown Lane, Dorchester-On-Thames, Wallingford, England, OX10 7LH
<b>Legal status</b>	Private company limited by shares, registered in England and Wales

# Ocquila Therapeutics Limited

## Contents

	Page
Directors' report	1
Balance sheet	2
Notes to the financial statements	3

**Ocquila Therapeutics Limited**  
**Directors' report for the period ended 31 December 2018**

The directors present their report and unaudited financial statements for the period from incorporation (24 April 2018) to 31 December 2018.

**Principal activity**

Ocquila Therapeutics Limited is engaged in research and experimental development on biotechnology. The company was dormant throughout the period ended 31 December 2018.

**Directors' responsibilities statement**

The directors are responsible for preparing the Directors' report and the financial statements in accordance with applicable law and regulations.

Company law requires the directors to prepare financial statements for each financial period.

Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgments and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

**Directors**

The directors who served during the period were:

Peter John Nolan (appointed 1 November 2018)

Sara Mary Hall (appointed 1 November 2018)

John Dawson (appointed 24 April 2018, resigned 1 November 2018)

Kristoff Rademan (appointed 24 April 2018, resigned 1 November 2018)

Stuart Paynter (appointed 24 April 2018, resigned 1 November 2018)

This report has been prepared in accordance with the provisions in Part 15 of the Companies Act 2006 applicable to companies subject to the small companies regime.

This report was approved by the directors on 3 May 2019 and signed on behalf of the board by:



**Peter Nolan**  
Director

**Ocquila Therapeutics Limited**  
**Balance sheet at 31 December 2018**

	Notes	2018 £
Debtors: amounts falling due within one year	4	100
<b>Net current assets</b>		<b>100</b>
<b>Total assets less current liabilities</b>		<b>100</b>
<b>Net assets</b>		<b>100</b>
<b>Capital and reserves</b>		
Called up share capital	5	100
Profit and loss account		-
<b>Shareholders' funds (deficit)</b>		<b>100</b>

For the period ended 31 December 2018 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with FRS 102 Section 1A - small entities.

The financial statements were approved by the Board of Directors on 3 May 2019.

Signed on behalf of the board by:



**Peter Nolan**  
Director

# Ocquila Therapeutics Limited

## Notes to the accounts for the period ended 31 December 2018

### 1. Accounting policies

#### Basis of preparation

The financial statements are prepared under the historical cost convention and in accordance with FRS 102.

#### Accounting period

The company was incorporated on 24 April 2018 under the name Ocquila (UK) Limited. On 24 January 2019 the name was changed to Ocquila Therapeutics Limited. These accounts are for the period 24 April 2018 to 31 December 2018. During that period the company was dormant.

#### Cash flow

The financial statements do not include a cash flow statement because the company, as a small reporting entity, is exempt from the requirement to prepare such a statement.

### 2. Employee numbers

The average number of persons employed by the company was:

Period ended  
31 December  
2018  
£

2

### 3. Debtors – amounts falling due within one year

Other debtors

2018  
£  
100  
**100**

### 4. Share capital

Allotted, called up and fully paid:  
10,000 Ordinary shares of 1p each

2018  
£  
100  
**100**

On incorporation on 24 April 2018 10,000 Ordinary shares of 1p each were issued at par value, fully paid

### 5. Events after the balance sheet

Subsequent to the year end on 21 March 2019 a further 257 ordinary shares of 1p each were allotted at par value, fully paid.